Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent
source: Blood Cells, Molecules and Diseases
year: 2018
authors: Rigano P, De Franceschi L, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL
summary/abstract:We conducted the first nation-wide cohort study of sickle cell disease (SCD) in Italy, a Southern European country exposed to intense recent flux migration from endemic areas for SCD. We evaluate the impact of hydroxyurea on a total of 652 pediatric and adult patients from 33 Reference Centers for SCD (mean age 24.5±15years, 51.4% males). Hydroxyurea median treatment duration was 7years (range: <1year to 29years) at a mean therapeutic dose of 18±4.7mg/kg/day. Hydroxyurea was associated with a significant increase in mean total and fetal hemoglobin and a significant decrease in mean hemoglobin S, white blood and platelet counts, and lactate dehydrogenase levels. Hydroxyurea was associated with a significant reduction in the incidence of acute chest syndrome (-29.3%, p<0.001), vaso-occlusive crisis (-34.1%, p<0.001), hospitalization (-53.2%, p<0.001), and bone necrosis (-6.9%, p<0.001). New silent cerebral infarction (SCI) occurred during treatment (+42.4%, p<0.001) but not stroke (+0.5%, p=0.572). These observations were generally consistent upon stratification for age, descent (Caucasian or African), genotype (βS/βS, βS/β0 or βS/β+) and duration of treatment (< or >=10years). There were no new safety concerns observed compared to those commonly reported in the literature. Our study, conducted on a large population of patients with different descent and compound state supports the benefits of hydroxyurea therapy as a treatment option. Registered at clinical trials.gov (NCT02709681).
organization: Azienda Ospedaliera-Università di Padova, Padua, Italy; University of Verona, AOUI Verona, Policlinico GB Rossi, Verona, Italy; University of Turin, Italy; Imperial College London, UK; "Ca' Granda" Ospedale Maggiore Policlinico Foundation IRCCS, Italy; Campus of Haematology Franco e Piera Cutino-A.O.O.R. "Villa Sofia-Cervello", Palermo, Italy; SIMTI Ragusa, Italy; San Gerardo Hospital, Monza, Italy; Azienda Ospedaliera-Università di Modena, Italy; Galliera Hospital, ItalyDOI: 10.1016/j.bcmd.2017.08.017
read more full text
Related Content
-
Cheryl Mensah, MDCheryl Mensah is an Assistant Professor ...
-
Sickle Cell Disease Association of Illinois Management of Sickle Cell Disease ConferenceThe Sickle Cell Disease Association of I...
-
Only 21% of Kids with ADHD and SCD Are Treated for Attention DeficitA study of children with sickle cell dis...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution net...Emmaus Life Sciences, Inc. announces...
-
GBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
-
Mona Robbins, PhDDr. Mona Robbins is an Associate Profess...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.